Background: Arterial calcification (AC) is frequent in patients with end stage renal disease
and is also considered a risk factor for later morbidity and mortality. However, long-term …

Results Baseline and first-year serum osteoprotegerin levels were significantly higher in the
progressive than nonprogressive group (17.39±9.67 versus 12.90±6.59 pmol/L, P= 0.02; …

Background Vascular calcification contributes to morbidity and mortality in patients with
ESRD on maintenance hemodialysis. Aims To study the relationship between osteocalcin …

Background. Cardiovascular disease is the leading cause of death in the chronic kidney
disease (CKD) population. The mechanisms of vascular damage are not fully understood …

It is of interest that in the general population, low bone mass is associated with a higher
mortality rate due to atherosclerotic cardiovascular disease. In addition, the degree of aortic …

This study aimed to investigate the relationship of four chronic kidney disease–mineral and
bone disorder (CKD–MBD) biomarkers, including intact parathyroid hormone (PTH) …

Background and aims Vascular calcification (VC) and atherosclerosis are associated with an
increased cardiovascular morbimortality in chronic kidney disease (CKD). Osteoprotegerin …

The aim of the study was to assess the factors potentially involved in coronary artery
calcifications (CAC) in end-stage renal disease patients. 253 hemodialysis (HD) patients (92 …

Background: Vascular calcification often occurs in patients with uremia. As osteopontin
(OPN) is not only involved in the physiological but also the pathological calcification of …

Background Osteoprotegerin (OPG), sclerostin and DKK1 constitute opposite bone turnover
inhibitors, OPG inhibiting osteoclastogenesis while sclerostin and DKK1 exerting their …